CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
Please provide your email address to receive an email when new articles are posted on . All-cause mortality in COPD patients was “strongly predicted” by diffusing capacity of the lung for carbon ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
Background—Pulmonary diffusing capacity for carbon monoxide (Dlco), alveolar capillary membrane diffusing capacity (Dm), and pulmonary capillary blood volume (Vc) are all significantly reduced after ...
Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Impairment of lung diffusion capacity, which correlated ...
You have full access to this article via your institution. The reduction in the patients’ diffusing capacity was marked, and for women and men, respectively, DLCO was 6.09 and 8.56 mmol/kPa/min ...
Background Current guidelines for the evaluation of chronic obstructive pulmonary disease (COPD) do not recommend screening for pulmonary hypertension (PH), despite the high prevalence and impact on ...
February 21, 2011 (Orlando, Florida) — In patients taking bleomycin for germ cell tumors, the use of lung function testing to monitor for drug-induced pneumonitis is controversial. A new study ...
Extending the use of a continuous positive airway pressure (CPAP) treatment in premature infants by two weeks significantly increases lung volume and lung diffusion capacity, according to a new study.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results